Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  
eqs_en 
0 27.10.22
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
eqs_en 
0 25.10.22
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
eqs_en 
0 21.10.22
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
eqs_en 
0 21.10.22
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
eqs_en 
0 21.10.22
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
eqs_en 
0 21.10.22
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
eqs_en 
0 18.10.22
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
eqs_en 
0 17.10.22
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
eqs_en 
0 28.09.22
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
eqs_en 
0 28.09.22
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
eqs_en 
0 20.09.22
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
eqs_en 
0 16.09.22
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
eqs_en 
0 31.08.22
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
eqs_en 
0 31.08.22
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
eqs_en 
0 25.08.22
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
eqs_en 
0 11.08.22
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
eqs_en 
0 10.08.22
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022
eqs_en 
0 04.08.22
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
eqs_en 
0 03.08.22
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
eqs_en 
0 03.08.22
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
eqs_en 
0 28.07.22
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
eqs_en 
0 28.07.22
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
eqs_en 
0 26.07.22
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
eqs_en 
0 26.07.22
DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
eqs_en 
0 26.07.22